uniQure Reports Q3 2026 Results, $61.2 Million Net Loss and $768.4 Million in Cash

What happened

uniQure reported third-quarter 2026 revenue of $5.2 million and a net loss of $61.2 million, or $0.88 per ordinary share. It had $768.4 million in cash, equivalents and investment securities at September 30, which it expects to fund operations into 2030. The FDA accepted its Huntington’s disease gene therapy application for Priority Review, with a target decision date of May 1, 2027.

Confirmed

Global impact / market context

The reported cash balance and expected funding runway indicate uniQure can continue developing its therapy without relying immediately on new funding, although the company is still reporting substantial losses. FDA review creates a potential route to earlier U.S. approval, while the decision and confirmatory study requirements remain important to future revenue prospects.

Analyst inference

Revenue rose from $3.7 million a year earlier, but research and development and administrative costs also increased, while the net loss narrowed from $80.5 million. For investors, the central tension is whether the regulatory progress can eventually support sales before operating costs consume the available cash.

Analyst inference

What to watch

1. Watch for the FDA’s decision by the stated May 1, 2027 target date; approval or delay would change the timing of potential U.S. sales. Confirmed
2. Track details and progress of the confirmatory study, which is a follow-up trial intended to verify treatment benefit; its design may affect regulatory requirements and spending. Confirmed
3. Compare future cash balances with research and administrative costs to assess whether the expected funding runway into 2030 remains plausible as development continues. Analyst inference

Evidence

• Original source link unavailable